(Q24240504)

4

0 references

Andrea Cipriani

5

0 references

Glyn Lewis

8

0 references

Rachel Churchill

1

0 references

Deborah Caldwell

2

0 references

Toshi A Furukawa

object named as

Toshi A Furukawa

6

0 references

Hugh McGuire

3

object named as

Hugh McGuire

0 references

Rachel Churchill

1 reference

ORCID Public Data File 2021

Norio Watanabe

Cochrane Database of Systematic Reviews

7

object named as

Norio Watanabe

0 references

publication date

15 April 2009

0 references

published in

0 references

cites work

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

"Wish bias" in antidepressant drug trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Industry sponsorship and authorship of clinical trials over 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Fluoxetine versus other types of pharmacotherapy for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Are we going to increase the use of antidepressants up to that of benzodiazepines?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Prevalence, nature, and comorbidity of depressive disorders in primary care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Australian and New Zealand clinical practice guidelines for the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Diagnostic Criteria for Use in Psychiatric Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Low dosage tricyclic antidepressants for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Imputing missing standard deviations in meta-analyses can provide accurate results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

The economic burden of depression in the US: societal and patient perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Amitriptyline for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Clinician's judgments of mental health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

A consumer's guide to subgroup analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Reboxetine, the first selective noradrenaline reuptake inhibitor antidepressant: Efficacy and tolerability in 2613 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

A systematic review of newer pharmacotherapies for depression in adults: evidence report summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Imputing response rates from means and standard deviations in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

Reboxetine: tolerability and safety profile in patients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

inferred from DOI database lookup

7 January 2021

based on heuristic

Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852

inferred from DOI database lookup

7 January 2021

based on heuristic

Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007852